Alagille syndrome is a complex genetic condition that primarily affects the liver, but can also impact the heart, blood vessels, and other organs. Managing this condition requires a combination of treatments aimed at controlling symptoms, preventing complications, and maintaining quality of life. While traditional therapies have helped many patients, new research is opening doors to more targeted approaches that may offer relief where older treatments have fallen short.

Understanding the Goals of Treatment in Alagille Syndrome

When doctors approach the treatment of Alagille syndrome, their main focus is on managing the symptoms that most significantly affect a patient’s daily life. The condition can vary dramatically from person to person, even within the same family. Some individuals experience only mild symptoms, while others face severe complications that require intensive medical intervention. This variability means that treatment plans must be highly individualized, taking into account which organs are affected and how severely.^[1]

The primary goals of treatment include reducing the buildup of bile (a digestive fluid produced by the liver) in the body, managing the intense itching that can make daily life unbearable, ensuring proper nutrition and growth in children, and preventing or treating complications that affect the heart, kidneys, and other organs. Since Alagille syndrome is a genetic condition present from birth, treatment often begins in infancy or early childhood and continues throughout life.^[2]

Treatment strategies fall into two main categories: standard therapies that have been used for years to manage symptoms, and newer experimental treatments being studied in clinical trials. Both approaches play important roles, and many patients benefit from a combination of traditional and innovative care. Medical societies and healthcare organizations provide guidelines to help doctors choose the most appropriate treatments based on current evidence and patient needs.^[3]

Standard Medical Treatment for Alagille Syndrome

The cornerstone of managing Alagille syndrome involves several established medical therapies, each targeting different aspects of the condition. One of the most commonly prescribed medications is ursodeoxycholic acid (also known as ursodiol or UDCA). This medication works by helping bile flow more easily from the liver to the intestines. By improving bile flow, ursodiol can help reduce the buildup of bile acids in the body, which may decrease liver damage and relieve some of the yellowish discoloration of the skin. Healthcare providers typically prescribe this medication for long-term use, and patients may take it for years or even throughout their lifetime.^[8]

The severe itching (called pruritus) that many people with Alagille syndrome experience can be one of the most challenging symptoms to manage. This itching is not like a typical skin irritation—it can be so intense that it disrupts sleep, causes skin damage from constant scratching, and significantly affects emotional well-being. To address this symptom, doctors may prescribe several different types of medications. Cholestyramine is a medication that binds to bile acids in the intestines, preventing them from being reabsorbed into the bloodstream. By reducing the amount of bile acids circulating in the body, it can help decrease itching.^[11]

Another medication used for itching is rifampin, an antibiotic that, through mechanisms not fully understood, can help reduce the sensation of itching in cholestatic liver disease. Naltrexone, a medication that blocks certain receptors in the brain related to pain and itching signals, has also been used successfully in some patients. For nighttime itching that interferes with sleep, doctors may recommend antihistamines such as hydroxyzine or diphenhydramine, which can help patients rest more comfortably. It’s important to note that these medications work differently for different people, and finding the right treatment often requires trying several options.^[11]

Nutrition plays a critical role in managing Alagille syndrome. Because the condition affects the body’s ability to absorb fats and fat-soluble vitamins (vitamins A, D, E, and K), many children with Alagille syndrome struggle with poor growth and development. Doctors monitor vitamin levels regularly through blood tests and prescribe supplements to correct deficiencies. These supplements often come in special water-soluble forms that are easier for the body to absorb when bile flow is reduced. Children may also need high-calorie nutritional supplements to support adequate growth. In some cases, doctors recommend feeding through a nasogastric tube (a tube that goes through the nose into the stomach) or a gastrostomy tube (a tube placed directly into the stomach through the abdomen) to ensure children receive enough calories and nutrients.^[9]

Managing the high cholesterol levels that often occur in Alagille syndrome is another important aspect of care. When bile cannot flow properly from the liver, cholesterol can accumulate to very high levels in the blood. This can lead to the formation of xanthomas—yellowish, fatty deposits that form under the skin, particularly on the joints, buttocks, and palms. Interestingly, the type of cholesterol that builds up in Alagille syndrome (called lipoprotein-X) is not the same as the cholesterol that causes heart disease, so patients do not have an increased risk of heart attacks or strokes from high cholesterol alone. However, when xanthomas become large or numerous, they can interfere with movement or cause cosmetic concerns. In severe cases, doctors have used cholesterol-lowering medications called statins, though these drugs are not routinely recommended for children and their use in Alagille syndrome remains uncommon.^[10]

For patients who develop complications related to the heart, kidneys, or blood vessels, specialists in those areas provide targeted treatments. Cardiologists may prescribe medications to manage heart problems or recommend procedures to address narrowed blood vessels. Patients with certain heart defects require antibiotics before dental or surgical procedures to prevent infections. Regular monitoring through imaging studies and specialized tests helps doctors detect and treat complications early.^[14]

When medical treatments fail to control symptoms adequately, surgical options may be considered. One procedure called partial external biliary diversion (PEBD) creates a new pathway for bile to leave the body. During this surgery, a portion of the small intestine is used to connect the gallbladder to an opening in the abdomen. Bile then drains into a collection bag outside the body, reducing the amount of bile acids circulating in the bloodstream. This can significantly improve itching and other symptoms in some patients. However, this surgery requires ongoing management of the drainage system and is typically reserved for cases where other treatments have not been successful.^[8]

In the most severe cases, when the liver becomes severely damaged (a condition called cirrhosis) or when symptoms cannot be controlled with medication or surgery, liver transplantation may be necessary. Approximately 15 percent of people with Alagille syndrome eventually require a liver transplant. The decision to proceed with transplantation is complex and based on multiple factors including liver function, severity of itching, growth failure, and overall quality of life. Liver transplantation is a major procedure that carries risks and requires lifelong medication to prevent rejection of the new organ, but it can be life-saving and dramatically improve quality of life for patients with severe disease.^[9]

Treatment Approaches Under Investigation in Clinical Trials

The landscape of treatment for Alagille syndrome has changed significantly in recent years with the development of a new class of medications called ileal bile acid transporter (IBAT) inhibitors. These drugs represent a major advance in addressing one of the most debilitating symptoms of the condition—severe itching. Understanding how these medications work requires understanding what happens to bile acids in the body.

Normally, bile acids travel from the liver through bile ducts into the intestines, where they help digest fats. Most of these bile acids are then reabsorbed in the lower part of the small intestine (the ileum) and returned to the liver—a process called enterohepatic circulation. In Alagille syndrome, because bile ducts are missing or abnormal, bile acids accumulate in the liver and spill into the bloodstream, causing itching and other symptoms. IBAT inhibitors work by blocking the reabsorption of bile acids in the intestine, effectively acting as a “medical biliary diversion.” Instead of being recycled back to the liver, the bile acids are eliminated in the stool, reducing their levels in the blood and liver.^[10]

The first IBAT inhibitor approved for Alagille syndrome is maralixibat, which received approval from the U.S. Food and Drug Administration in September 2021 under the brand name Livmarli. This approval was based on results from the ICONIC clinical trial, a Phase 2 study that evaluated the safety and effectiveness of maralixibat in patients with Alagille syndrome who experienced severe itching. The trial was conducted at multiple medical centers and included children aged one year and older.^[10]

In the ICONIC trial, researchers measured how much patients scratched using standardized scales and also monitored levels of bile acids in the blood. Patients who received maralixibat showed significant improvements in both measures. The scratching scores decreased, meaning patients experienced less itching and scratched less frequently. Bile acid levels in the blood also dropped substantially. Additionally, the study found improvements in other symptoms related to cholestasis, including xanthomas (the fatty skin deposits), and some patients showed improved growth. The safety profile of maralixibat in the trial was generally favorable, with the most common side effect being diarrhea, which makes sense given that the medication works by preventing bile acid reabsorption in the intestines.^[13]

Following the ICONIC trial, long-term extension studies have followed patients for several years to understand the sustained effects of maralixibat. These studies, which tracked some patients for up to five years, showed that the benefits of the medication persisted over time. Patients who continued taking maralixibat maintained lower levels of itching and bile acids. Importantly, researchers observed that patients who stopped taking the medication (during placebo-controlled phases of the studies) saw their symptoms return to previous levels, providing strong evidence that the drug was responsible for the improvements.^[13]

In March 2023, the approval for maralixibat was expanded to include children as young as three months old, reflecting data showing that the medication could be used safely in this younger age group. This expansion is significant because symptoms of Alagille syndrome often appear in early infancy, and having an approved treatment option for very young patients fills an important gap in care.^[11]

A second IBAT inhibitor, odevixibat (brand name Bylvay), received FDA approval in June 2023 for treatment of cholestatic pruritus in patients with Alagille syndrome aged one year and older. This approval was based on results from the ASSERT trial, a Phase 3 clinical study that compared odevixibat to placebo. In this trial, patients receiving odevixibat experienced significantly greater reductions in scratching scores compared to those receiving placebo. The study demonstrated that scratching scores decreased by an average of 1.7 points in the odevixibat group, compared to 0.8 points in the placebo group—a statistically significant difference that translated into meaningful symptom relief for patients.^[11]

The approval of these IBAT inhibitors represents a significant milestone for the Alagille syndrome community. Before these medications became available, treatment options for itching were limited to older drugs that often provided inadequate relief. Many children continued to suffer from severe itching despite trying multiple medications, and some ultimately required liver transplantation primarily because of uncontrollable symptoms rather than liver failure itself. The availability of IBAT inhibitors now provides doctors and families with a targeted treatment that directly addresses the underlying mechanism causing itching.^[10]

Beyond IBAT inhibitors, other research approaches are being explored. Scientists are studying the fundamental biology of Alagille syndrome to better understand how mutations in the JAG1 and NOTCH2 genes lead to the various features of the condition. This research into the Notch signaling pathway—a critical system of communication between cells during development—may reveal new targets for treatment. Understanding exactly how disrupted Notch signaling causes bile duct abnormalities, heart defects, and other features of Alagille syndrome could lead to therapies that address the root causes of the condition rather than just managing symptoms.^[3]

Research is also focused on understanding why Alagille syndrome affects individuals so differently. Even people with identical genetic mutations can have vastly different symptoms and disease severity. Scientists are investigating whether other genetic factors or environmental influences modify how the disease develops. This knowledge could eventually allow doctors to predict which patients are at highest risk for severe complications and tailor treatments accordingly.^[14]

Investigators continue to study long-term outcomes for patients with Alagille syndrome. Clinical trials are collecting data on how various treatments affect not only symptoms but also overall health, quality of life, need for liver transplantation, and survival. Understanding these long-term effects is essential for guiding treatment decisions and helping families know what to expect as children with Alagille syndrome grow into adulthood.^[21]

Most common treatment methods

• Medications to improve bile flow and reduce symptoms
  • Ursodeoxycholic acid (ursodiol) to stimulate bile flow from the liver to the intestines
  • Cholestyramine to bind bile acids in the intestines and reduce itching
  • Rifampin to help reduce severe itching through effects on liver metabolism
  • Naltrexone (opioid receptor antagonist) for treatment of itching
  • Antihistamines to help with sleep disruption caused by itching
• IBAT (ileal bile acid transporter) inhibitors
  • Maralixibat (Livmarli) approved for patients 3 months and older to treat cholestatic pruritus
  • Odevixibat (Bylvay) approved for patients 1 year and older to treat cholestatic pruritus
  • These medications work by interrupting the recycling of bile acids, reducing their buildup in the body
  • Clinical trials showed significant reductions in itching and improvements in quality of life
• Nutritional support and vitamin supplementation
  • Fat-soluble vitamins (A, D, E, K) in water-miscible or TPGS formulations for better absorption
  • Zinc supplementation when deficiency is detected
  • High-calorie nutritional supplements to support growth
  • Nasogastric or gastrostomy tube feeding when oral intake is insufficient
• Surgical interventions
  • Partial external biliary diversion (PEBD) to reduce bile acid circulation and improve itching
  • Liver transplantation for end-stage liver disease, intractable itching, or severe growth failure
  • Cardiac procedures to address heart defects such as pulmonary stenosis
• Supportive care and symptom management
  • Skin care measures including moisturizers, short baths, and nail trimming to minimize scratching damage
  • Monitoring and treatment of vitamin deficiencies
  • Regular cardiac, ophthalmologic, and renal evaluations
  • Antibiotic prophylaxis for patients with certain heart defects to prevent infections